Skip to main content
Erschienen in: Familial Cancer 4/2014

01.12.2014 | Original Article

Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations

verfasst von: Stephen E. Langabeer, Karl Haslam, Jennifer Linders, Melanie J. Percy, Eibhlin Conneally, Amjad Hayat, Brian Hennessy, Maeve Leahy, Karen Murphy, Margaret Murray, Fionnuala Ni Ainle, Patrick Thornton, Jeremy Sargent

Erschienen in: Familial Cancer | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The myeloproliferative neoplasms (MPN) are clonal, hematological malignancies that include polycythemia vera, essential thrombocythemia and primary myelofibrosis. While most cases of MPN are sporadic in nature, a familial pattern of inheritance is well recognised. The phenotype and status of the commonly acquired JAK2 V617F, CALR exon 9 and MPL W515L/K mutations in affected individuals from a consecutive series of ten familial MPN (FMPN) kindred are described. Affected individuals display the classical MPN phenotypes together with one kindred identified suggestive of hereditary thrombocytosis. In affected patients the JAK2 V617F mutation is the most commonly acquired followed by CALR exon nine mutations with no MPL W515L/K mutations detected. The JAK2 V617F and CALR exon 9 mutations appear to occur at approximately the same frequency in FMPN as in the sporadic forms of these diseases. The familial nature of MPN may often be overlooked and accordingly more common than previously considered. Characterisation of these FMPN kindred may allow for the investigation of molecular events that contribute to this inheritance.
Literatur
1.
Zurück zum Zitat Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573–582PubMedCrossRef Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573–582PubMedCrossRef
2.
Zurück zum Zitat McMahon B, Stein BL (2013) Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 39:101–111PubMed McMahon B, Stein BL (2013) Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost 39:101–111PubMed
3.
Zurück zum Zitat Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673–683PubMedCrossRef Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673–683PubMedCrossRef
4.
Zurück zum Zitat Santos FP, Verstovsek S (2012) Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am 26:1083–1099PubMedCrossRef Santos FP, Verstovsek S (2012) Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am 26:1083–1099PubMedCrossRef
5.
6.
Zurück zum Zitat Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390PubMedCrossRef Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390PubMedCrossRef
7.
Zurück zum Zitat Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405PubMedCentralPubMedCrossRef Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Gong JZ, Cook JR, Greiner TC et al (2013) Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report from the Association for Molecular Pathology. J Mol Diagn 15:733–744PubMedCrossRef Gong JZ, Cook JR, Greiner TC et al (2013) Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report from the Association for Molecular Pathology. J Mol Diagn 15:733–744PubMedCrossRef
9.
Zurück zum Zitat Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:1128–1138PubMedCentralPubMedCrossRef Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:1128–1138PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Rumi E (2008) Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol 26:131–138PubMedCrossRef Rumi E (2008) Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol 26:131–138PubMedCrossRef
11.
Zurück zum Zitat Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A (2012) Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2 V617F in the occurrence of complications. Blood Cells Mol Dis 49:170–176PubMedCrossRef Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A (2012) Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2 V617F in the occurrence of complications. Blood Cells Mol Dis 49:170–176PubMedCrossRef
12.
Zurück zum Zitat Ranjan A, Penninga E, Jelsig AM, Hasselbalch H, Bjerrum OW (2013) Inheritance of the chronic myeloproliferative neoplasms: a systematic review. Clin Genet 83:99–107PubMedCrossRef Ranjan A, Penninga E, Jelsig AM, Hasselbalch H, Bjerrum OW (2013) Inheritance of the chronic myeloproliferative neoplasms: a systematic review. Clin Genet 83:99–107PubMedCrossRef
13.
Zurück zum Zitat Bento C, Percy MJ, Gardie B et al (2014) Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat 35:15–26PubMedCrossRef Bento C, Percy MJ, Gardie B et al (2014) Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat 35:15–26PubMedCrossRef
15.
Zurück zum Zitat Mead AJ, Rugless MJ, Jacobsen SE, Schuh A (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 366:967–969PubMedCrossRef Mead AJ, Rugless MJ, Jacobsen SE, Schuh A (2012) Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 366:967–969PubMedCrossRef
16.
Zurück zum Zitat Jones AV, Chase A, Silver RT et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446–449PubMedCentralPubMedCrossRef Jones AV, Chase A, Silver RT et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446–449PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Olcaydu D, Harutyunyan A, Jäger R et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450–454PubMedCrossRef Olcaydu D, Harutyunyan A, Jäger R et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450–454PubMedCrossRef
18.
Zurück zum Zitat Kilpivaara O, Mukherjee S, Schram AM et al (2009) A germline SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455–459PubMedCentralPubMedCrossRef Kilpivaara O, Mukherjee S, Schram AM et al (2009) A germline SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455–459PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Olcaydu D, Skoda RC, Looser R et al (2009) The GGCC haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924–1926PubMedCrossRef Olcaydu D, Skoda RC, Looser R et al (2009) The GGCC haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924–1926PubMedCrossRef
20.
Zurück zum Zitat Jones AV, Campbell PJ, Beer PA et al (2010) The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115:4517–4523PubMedCentralPubMedCrossRef Jones AV, Campbell PJ, Beer PA et al (2010) The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115:4517–4523PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissue. International Agency for Research on Cancer, Lyon Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissue. International Agency for Research on Cancer, Lyon
22.
Zurück zum Zitat Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedCrossRef Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedCrossRef
23.
Zurück zum Zitat Daly S, Conneally E, Langabeer SE (2009) Identification of the MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction. Acta Haematol 121:221–222PubMedCrossRef Daly S, Conneally E, Langabeer SE (2009) Identification of the MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction. Acta Haematol 121:221–222PubMedCrossRef
24.
Zurück zum Zitat Percy MJ, Scott LM, Erber WN et al (2007) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 92:1607–1614PubMedCrossRef Percy MJ, Scott LM, Erber WN et al (2007) The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 92:1607–1614PubMedCrossRef
25.
Zurück zum Zitat Martinez-Avilés L, Álvarez-Larrán A, Besses C et al (2012) Clinical significance of clonality assessment in JAK2 V617F-negative essential thrombocythemia. Ann Hematol 91:1555–1562PubMedCrossRef Martinez-Avilés L, Álvarez-Larrán A, Besses C et al (2012) Clinical significance of clonality assessment in JAK2 V617F-negative essential thrombocythemia. Ann Hematol 91:1555–1562PubMedCrossRef
27.
Zurück zum Zitat Maffioli M, Genoni A, Caramazza D et al (2014) Looking for CALR mutations in familial myeloproliferative disorders. Leukemia 28:1357–1360PubMedCrossRef Maffioli M, Genoni A, Caramazza D et al (2014) Looking for CALR mutations in familial myeloproliferative disorders. Leukemia 28:1357–1360PubMedCrossRef
28.
Zurück zum Zitat Rumi E, Harutyunyan AS, Pietra D et al (2014) CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood 123:2416–2419PubMedCrossRef Rumi E, Harutyunyan AS, Pietra D et al (2014) CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood 123:2416–2419PubMedCrossRef
29.
Zurück zum Zitat Rumi E, Harutyunyan AS, Casetti I et al (2014) A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol 89:117–118PubMedCrossRef Rumi E, Harutyunyan AS, Casetti I et al (2014) A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol 89:117–118PubMedCrossRef
30.
Zurück zum Zitat Etheridge SL, Cosgrove ME, Sangkhae V et al (2014) A novel activating, germline JAK2 mutation, JAK2 R564Q, causes familial essential thrombocytosis. Blood 123:1059–1068PubMedCrossRef Etheridge SL, Cosgrove ME, Sangkhae V et al (2014) A novel activating, germline JAK2 mutation, JAK2 R564Q, causes familial essential thrombocytosis. Blood 123:1059–1068PubMedCrossRef
31.
Zurück zum Zitat Rumi E, Passamonti F, Della Porta MG et al (2007) Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 35:5630–5635CrossRef Rumi E, Passamonti F, Della Porta MG et al (2007) Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 35:5630–5635CrossRef
32.
Zurück zum Zitat Olcaydu D, Rumi E, Harutyunyan A et al (2011) The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 96:367–374PubMedCentralPubMedCrossRef Olcaydu D, Rumi E, Harutyunyan A et al (2011) The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 96:367–374PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Scott LM, Rebel VI (2012) JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol 87:1028–1036PubMedCentralPubMedCrossRef Scott LM, Rebel VI (2012) JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? Am J Hematol 87:1028–1036PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Anderson LA, Duncombe AS, Hughes M et al (2012) Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 87:175–182PubMedCrossRef Anderson LA, Duncombe AS, Hughes M et al (2012) Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 87:175–182PubMedCrossRef
Metadaten
Titel
Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations
verfasst von
Stephen E. Langabeer
Karl Haslam
Jennifer Linders
Melanie J. Percy
Eibhlin Conneally
Amjad Hayat
Brian Hennessy
Maeve Leahy
Karen Murphy
Margaret Murray
Fionnuala Ni Ainle
Patrick Thornton
Jeremy Sargent
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2014
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9743-2

Weitere Artikel der Ausgabe 4/2014

Familial Cancer 4/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.